New and updated preclinical and clinical data presented by biopharma firms at the Society for Immunotherapy of Cancer’s annual meeting Nov. 9-14, including: 4D, Acepodia, Advaxis, Affimed, Agenus, Alkermes, Alx, Amgen, Beam, Bioinvent, Checkpoint, Codiak, Genocea, Huya, Kleo, Oncolytics, Oncosec, Rubius, Transgene, Vigeo, Windmil.